This suggests a potential strategy for METTL1-overexpressing tumours, where the use of combination therapies, including METTL1 inhibitors, may synergise with chemotherapy or senolytic therapy to promote more effective elimination of tumour-initiating cells and persistent cancer cells. Here, METTL1 is linked to neoplasm.